<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740753</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00002377</org_study_id>
    <secondary_id>HDE 2377</secondary_id>
    <nct_id>NCT00740753</nct_id>
  </id_info>
  <brief_title>Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option</brief_title>
  <acronym>Y-90HDE</acronym>
  <official_title>A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fewer than 15% of hepatoma patients are suitable candidates for surgical removal of their&#xD;
      cancer. The purpose of this protocol is to provide supervised access at Oregon Health and&#xD;
      Science University to Y-90 treatment to provide these patients access to an alternate&#xD;
      therapy. The radioactive beads are placed directly near or into the liver tumor with the&#xD;
      intention of destroying the tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive Y-90 (yttrium) glass microspheres via percutaneous hepatic arterial&#xD;
      infusion. Patients amy be retreated between 30-90 days after initial infusion. After&#xD;
      completion of therapy, patients are followed for 30 days and then every 3 months for up to 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 28, 2021</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.</measure>
    <time_frame>2 weeks, 1 month and then every 3 months</time_frame>
    <description>Tumors will decrease in size</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Hepatoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>yttrium 90 (TheraSphere) administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Yttrium 90 (TheraSphere)</intervention_name>
    <description>Y-90 embedded glass microspheres</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Yttrium - 90</other_name>
    <other_name>Y-90</other_name>
    <other_name>TheraSphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of HCC&#xD;
&#xD;
          -  Cancer is unresectable&#xD;
&#xD;
          -  ECOG Score 0-2&#xD;
&#xD;
          -  Age of 18 yrs or over&#xD;
&#xD;
          -  Able to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to angiography and selective visceral catheterization&#xD;
&#xD;
          -  Portal hypertension with portal venous shunt away from the liver&#xD;
&#xD;
          -  Evidence of potential delivery of &gt; 16.5 mCi of radiation to the lungs&#xD;
&#xD;
          -  Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after&#xD;
             application of established angiographic techniques to stop such flow&#xD;
&#xD;
          -  Significant extrahepatic disease representing an imminent life-threatening outcome&#xD;
&#xD;
          -  Severe liver dysfunction or pulmonary insufficiency&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Significant underlying medical or psychiatric illness&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Kolbeck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2008</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Kenneth J Kolbeck MD PhD</investigator_full_name>
    <investigator_title>Associate Professor, Charles T. Dotter Department of Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>liver tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>hepatoma</keyword>
  <keyword>yttrium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

